Jan 11, 2022
Dr. Hing Wong is the Founder and CEO of HCW Biologics and a pioneer in the field of inflammaging which recognizes that as we age, chronic inflammation can trigger a range of age-related diseases. Their proprietary platform TOBI is using a unique Tissue FactOr-Based Scaffold to build multifunctional fusion molecules to put a variety of immunotherapeutic molecules together in a drug using subcutaneous injection.
Hing explains, "There is a lot of really strong scientific evidence demonstrating that when we get old, we basically accumulate chronic inflammation. This chronic inflammation with aging basically makes up the word inflammaging. What it does is the accumulation of chronic inflammation and is the cause of a lot of major diseases in humans, such as cancer, neurodegenerative disease, Alzheimer's disease, Parkinson's disease also diabetes. So our mission is to try to find drugs, immunotherapeutic in particular, to disrupt this inflammaging in a sense to disrupt the chronic inflammation accumulation during the aging process."
"Our idea is to get rid of these chronic inflammation sources induced by chemotherapy. So, on the one hand, you can enhance the chemotherapy's efficacy against cancer and also can completely eliminate the side effects caused by the chemotherapy. So that's another reason we chose cancer being our first indication."
#HCW #Inflammaging #Aging #Longevity #HealthSpan #LifeSpan
